Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations

Medicine, Genetics, Oncology +17

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

Eugène van Puijenbroek, Andrew Bate, Hubert G.M. Leufkens et al. · Pharmacoepidemiology and Drug Safety · 2002 · 1.3K citations

Pharmacy, Pharmacology, Clinical Pharmacology +16

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe‐Elie Salem, Ali Manouchehri, Melissa Moey et al. · The Lancet Oncology · 2018 · 1.2K citations

Life Sciences, Immunology, Pharmacology +16

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +14